Home Alzheimer’s Disease Palbociclib Plus Endocrine Therapy Is Less Toxic Than Standard Capecitabine for Treating...

Palbociclib Plus Endocrine Therapy Is Less Toxic Than Standard Capecitabine for Treating AI-Resistant MBC

With regard to progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who were resistant to aromatase inhibitors (AIs), there was no statistical superiority of palbociclib (Ibrance) plus endocrine therapy (ET) over capecitabine, according to results from the phase 3 PEARL study (NCT02028507), published in Annals of Oncology.1

However, the combination of palbociclib and ET did demonstrate a more favorable safety profile and improved quality of life among this patient population.

“In addition, while the PEARL trial did not meet its coprimary objectives, it still provides evidence and suggestions for the management of hormone receptor–positive AI-resistant MBC,” wrote the study authors, who were led by Miguel Martin, MD, PhD.

The randomized, multicenter, international, open-label, controlled phase 3 PEARL study evaluated patients with AI-resistant MBC in 2…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Recent Comments